
BGM (BGM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
53.0M
Total Liabilities
8.9M
Shareholders Equity
44.1M
Debt to Equity
0.20
Cash Flow Metrics
Revenue & Profitability Trend
BGM Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 25.1M | 46.5M | 64.9M | 57.1M | 50.0M |
Cost of Goods Sold | 21.0M | 44.7M | 58.6M | 51.5M | 42.5M |
Gross Profit | 4.1M | 1.8M | 6.2M | 5.6M | 7.5M |
Gross Margin % | 16.4% | 3.8% | 9.6% | 9.9% | 15.1% |
Operating Expenses | |||||
Research & Development | 1.4M | 568.5K | 1.2M | - | - |
Selling, General & Administrative | 3.3M | 3.8M | 2.9M | 3.3M | 2.7M |
Other Operating Expenses | -206.4K | -192.4K | -413.7K | -564.1K | -1.1M |
Total Operating Expenses | 4.5M | 4.2M | 3.7M | 2.7M | 1.6M |
Operating Income | -357.4K | -2.4M | 2.5M | 3.0M | 5.9M |
Operating Margin % | -1.4% | -5.2% | 3.9% | 5.2% | 11.8% |
Non-Operating Items | |||||
Interest Income | - | - | 24.9K | - | - |
Interest Expense | - | - | - | 57.7K | 242.9K |
Other Non-Operating Income | -1.1M | -5.6M | -980.0K | 468.8K | 155.0K |
Pre-tax Income | -2.1M | -7.9M | 1.6M | 3.4M | 5.8M |
Income Tax | -620.0K | 219.2K | 194.3K | 255.1K | 864.9K |
Effective Tax Rate % | 0.0% | 0.0% | 12.5% | 7.6% | 14.9% |
Net Income | -1.5M | -8.1M | 1.4M | 3.1M | 4.9M |
Net Margin % | -6.0% | -17.5% | 2.1% | 5.4% | 9.9% |
Key Metrics | |||||
EBITDA | 1.8M | 4.2M | 4.6M | 3.7M | 7.2M |
EPS (Basic) | - | $-1.08 | $0.15 | $0.45 | $0.72 |
EPS (Diluted) | - | $-1.08 | $0.15 | $0.45 | $0.72 |
Basic Shares Outstanding | - | 7226480 | 7226480 | 6817857 | 7000000 |
Diluted Shares Outstanding | - | 7226480 | 7226480 | 6817857 | 7000000 |
Income Statement Trend
BGM Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 9.8M | 7.5M | 14.3M | 10.5M | 11.9M |
Short-term Investments | 8.3M | 14.9M | 0 | - | - |
Accounts Receivable | 1.5M | 2.0M | 815.3K | 1.7M | 1.1M |
Inventory | 5.0M | 5.0M | 8.9M | 12.5M | 12.0M |
Other Current Assets | - | - | -1 | - | - |
Total Current Assets | 29.8M | 34.5M | 30.0M | 40.4M | 37.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 243.9K |
Goodwill | 4.5M | 3.4M | 1.7M | 1.9M | 1.9M |
Intangible Assets | 4.5M | 3.4M | 1.7M | 1.9M | 1.9M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 424.5K | 10.8K | 385.8K | 616.0K | 540.6K |
Total Non-Current Assets | 23.2M | 16.7M | 34.5M | 35.0M | 10.6M |
Total Assets | 53.0M | 51.3M | 64.5M | 75.4M | 48.1M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.1M | 3.6M | 5.3M | 6.6M | 4.4M |
Short-term Debt | - | 553.3K | 1.7M | 7.9M | 7.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 8.8M | 6.7M | 9.2M | 18.2M | 18.4M |
Non-Current Liabilities | |||||
Long-term Debt | 0 | 24.6K | 72.5K | 106.2K | 155.7K |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 134.4K | 246.5K | 382.5K | 509.9K | 877.9K |
Total Liabilities | 8.9M | 6.9M | 9.6M | 18.7M | 19.3M |
Equity | |||||
Common Stock | 59.6K | 59.6K | 59.6K | 59.6K | 50.0K |
Retained Earnings | 4.3M | 5.9M | 15.5M | 14.7M | 12.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 44.1M | 44.4M | 55.0M | 56.7M | 28.8M |
Key Metrics | |||||
Total Debt | 0 | 577.8K | 1.8M | 8.0M | 7.6M |
Working Capital | 21.0M | 27.9M | 20.9M | 22.2M | 19.1M |
Balance Sheet Composition
BGM Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.5M | -8.1M | 1.4M | 3.1M | 4.9M |
Depreciation & Amortization | 1.2M | 1.1M | 1.2M | 1.2M | 1.2M |
Stock-Based Compensation | 0 | 0 | 20.0K | 0 | 0 |
Working Capital Changes | 390.2K | 691.8K | 7.8M | -775.6K | -3.0M |
Operating Cash Flow | -235.8K | -6.1M | 10.6M | 3.5M | 3.0M |
Investing Activities | |||||
Capital Expenditures | -2.9M | -1.8M | -3.2M | -3.5M | -449.8K |
Acquisitions | 0 | -28.4K | 0 | -706.7K | 0 |
Investment Purchases | -1.4M | -1.0M | 0 | -20.0M | 0 |
Investment Sales | 6.3M | 0 | 0 | 0 | 83.0K |
Investing Cash Flow | 2.0M | -2.9M | -3.2M | -24.2M | -366.8K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | 0 | -1.8M | 0 | - | 0 |
Debt Issuance | - | - | 3.2M | 7.8M | 7.1M |
Debt Repayment | -491.7K | -1.7M | -9.1M | -7.7M | -5.0M |
Financing Cash Flow | -983.5K | -4.6M | -11.9M | 16.3M | -2.9M |
Free Cash Flow | -3.4M | -3.4M | 9.4M | -3.1M | 4.6M |
Net Change in Cash | 786.2K | -13.5M | -4.5M | -4.3M | -193.0K |
Cash Flow Trend
BGM Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
15.00
Price to Book
4.06
Price to Sales
50.51
Profitability Ratios
Profit Margin
-26.32%
Operating Margin
-5.41%
Return on Equity
-16.52%
Return on Assets
-3.84%
Financial Health
Current Ratio
7.05
Debt to Equity
0.22
Beta
1.46
Per Share Data
EPS (TTM)
$-0.29
Book Value per Share
$1.85
Revenue per Share
$4.18
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bgm | 1.5B | 15.00 | 4.06 | -16.52% | -26.32% | 0.22 |
Zoetis | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 44.7B | 21.82 | 5.54 | 9.38% | 13.81% | 53.41 |
Ani Pharmaceuticals | 2.0B | 51.63 | 4.20 | -2.17% | -1.37% | 136.10 |
BioCryst | 1.8B | -19.94 | -4.26 | 18.68% | -6.41% | -1.75 |
Harrow | 1.4B | -78.02 | 28.45 | -19.03% | -4.49% | 469.08 |
Financial data is updated regularly. All figures are in the company's reporting currency.